Critical New HTA Developments in Europe: Challenges & Solutions
With Prof. Dr Lieven Annemans
Course Details
THE CONTENT
European HTA systems are undergoing significant change. While national differences in methodology and decision-making processes and criteria remain, increasing EU-level coordination is reshaping how companies must approach market and patient access strategies.
To succeed, pharma and biotech professionals involved in market and patient access planning need a solid grasp of the HTA landscape and how it is evolving. This course provides a practical introduction to current HTA dynamics in Europe, helping you make sense of both the fundamentals and the latest developments.
Over the course of one day, you will gain a better understanding of the variety in HTA processes and criteria across Europe and how these interact with EU-level developments.
If you are looking for a concise, expert-led overview of the latest HTA trends in Europe, with recommendations for access planning, this course is a must-attend.
Great overall introduction to the topic, with excellent details on the challenges to be dealt with in the new legislation. The interactive aspect and engaging presentation by Prof. Dr. Lieven Annemans, an obvious expert, were particularly valuable. The course deepened my understanding of HTA and provided a comprehensive overview of the topic.
Merck
Laura Bauer, Senior Manager, Global Policy & External Affairs - Germany - June 2024
THE EXPERT
Prof. Dr Lieven Annemans is one of Europe’s most respected voices in health economics and HTA.
He has experience in health economic evaluations across 20+ countries and numerous therapeutic areas.
He is a long-standing expert advisor in national and EU-level HTA initiatives, with deep insight into methodology, implementation, and policy.
He is an academic professor, past president of ISPOR, author of "Health Economics for Non-Economists", and has published more than 350 peer-reviewed papers. He's also a widely recognised speaker and trainer.
A CELforPharma faculty member since 2009, he is consistently praised for his engaging, pragmatic, and entertaining teaching style.
To get a flavour of Lieven’s expertise and teaching style, watch this recent educational webinar:
THE AUDIENCE & INTERACTIVE LEARNING FORMAT
This course is designed for pharma and biotech professionals who need a clear understanding of how HTA principles, policies, and practices affect market and patient access in Europe. It is especially valuable for executives working in:
Market Access
Pricing & Reimbursement
Clinical Development
Regulatory Affairs
Medical Affairs
Governmental Affairs
Health Economics
Marketing
The interactive format includes expert-led teaching, peer discussions, practical recommendations, and in-depth Q&A. You will learn directly from Prof. Dr Lieven Annemans and benefit from exchanging experiences with peers facing similar access challenges across Europe.
Great lecturer; the information covered during the training was very comprehensive, addressing both the basics and the latest developments. The overview of different models used in different EU countries was extremely valuable and the participant engagement in discussions was enriching. I highly recommend this course!
Insuvia
Monika Staniulyte, Regulatory Affairs Team Lead - Lithuania - June 2024
The different types of HTA processes in Europe and how they inform decision-making.
How HTA bodies combine a variety of evaluation criteria, and what this means for value assessment.
Key principles and common pitfalls in clinical evidence generation from an HTA perspective.
The role of Real-World Data in HTA, including its strengths, limitations, and appropriate use across the lifecycle.
What the Joint Clinical Assessment (JCA) will change, how to anticipate its implications, and how to prepare at a strategic level.
An excellent top-line overview of the practical application of health economics. The course covered a lot in a single day but remained digestible thanks to its clear format. I especially valued the discussion on current JCA developments. Peer input also added real value.
Kevin Veninga, Healthcare Communicator - The Netherlands - June 2025
| Definitions and Taxonomy of HTA: What HTA Is – and Is Not – and How It Functions in Decision-Making Contexts (~1 h) |
|
| Optimising the Mix of Criteria: Moving Beyond Cost-Effectiveness to Reflect Value, Need, and Societal Priorities (~1 h 30 min) |
|
| Generating Clinical Evidence: Designing Evidence That Stands Up to HTA Scrutiny (~45 min) |
|
| Lunch Break |
| The Increasing Need for Real-World Data (RWD): Managing Uncertainty and Evidence Gaps Across the Lifecycle (~1 h 15 min) |
|
| Towards a Joint Clinical Assessment (JCA) in the EU: What JCA Will Change — and What It Will Not (~1 h 30 min) |
|
| Summary & Final Discussion (~15 min) |
UPCOMING DATES & FORMATS - FEES
29 May 2026
Live online
Early bird € 1 570
(until 24/04/2026)
(Full fee € 1 770)
18 November 2026
Live online
Early bird € 1 570
(until 16/10/2026)
(Full fee € 1 770)
TIMING & LOCATION
Live Online: Zoom sessions between 9 AM and 5 PM CET (Brussels, Amsterdam, Paris time).
All practical details will be shared upon registration. For any questions, please contact Margherita Mutto or call +32 472 03 11 38 .
GROUP DISCOUNTS
Team discounts can be offered to 2 or more delegates from the same company.
Email Annelies Swaan for more details.
HOW TO REGISTER
Click the green “Register” button on your preferred course session.
The registration wizard will guide you through the process.Alternatively, download the offline registration form and send the completed form to Annelies Swaan.
PAYMENT OPTIONS
Credit Card: You’ll receive a secure payment link with your invoice (no immediate payment required).
Bank Transfer: Details provided with your invoice.
For help with registration, email Annelies Swaan or contact her by phone at +32 486 98 52 49.
INCLUDED IN THE REGISTRATION FEE
Access to a highly interactive, small-group online course (max 20 participants)
Course materials in both digital and hard copy format
Certificate of attendance signed by the experts and CELforPharma
VAT INFORMATION
Prices exclude VAT. VAT application depends on course format and your location:
Face-to-Face in Belgium: 21% Belgian VAT applies
Live online courses: The applicable VAT depends on your invoicing address. Contact your local VAT office for refund procedures where applicable.
TRANSFER & CANCELLATION POLICY
Flexible Transfer
If a registrant is unable to attend the scheduled course, they can avoid any cancellation charges by providing a suitable replacement participant.
Alternatively, the registrant may transfer once, on a 'space-available' basis and at no extra cost, to another course of the same value held within one year of the original course date, provided this is done at least three weeks prior to the event.
Registration Cancellation
Less than 14 days prior to the course date: The registrant is liable to pay the full invoiced registration fee.
Between 15 and 30 days prior to the course date: The registrant is liable to pay 50% of the invoiced registration fee.
More than 30 days prior to the course date: The registrant is liable to pay a cancellation fee of € 450 per registrant.
If a registrant postpones their participation to a future course and subsequently cancels again, no refund will be issued for the registration fees.
An excellent top-line overview of the practical application of health economics. The course covered a lot in a single day but remained digestible thanks to its clear format. I especially valued the discussion on current JCA developments. Peer input also added real value.
Kevin Veninga, Healthcare Communicator - The Netherlands - June 2025
Great overall introduction to the topic, with excellent details on the challenges to be dealt with in the new legislation. The interactive aspect and engaging presentation by Prof. Dr. Lieven Annemans, an obvious expert, were particularly valuable. The course deepened my understanding of HTA and provided a comprehensive overview of the topic.
Merck
Laura Bauer, Senior Manager, Global Policy & External Affairs - Germany - June 2024
The course and instructor were great. Lieven is clearly an expert in the field, with clear and articulate presentations. The interactions between attendees added to the experience, and I have gained valuable insights into the upcoming EU HTA changes. Highly recommended!
Novartis
Nick Riley, Senior Market Access Manager - Australia - June 2024
Great lecturer; the information covered during the training was very comprehensive, addressing both the basics and the latest developments. The overview of different models used in different EU countries was extremely valuable and the participant engagement in discussions was enriching. I highly recommend this course!
Insuvia
Monika Staniulyte, Regulatory Affairs Team Lead - Lithuania - June 2024
I got relevant information, it was refreshing also. The comparison of different countries' approaches and the excellent description of crucial parts of HTA were particularly useful. The experience from practice shared during the course enriched my understanding significantly.
Pharm-In
Dominik Grega, MA & HTA Manager - Slovakia - June 2024
People attending this course are typically also interested in the below courses.
Need help to find the right course? Email Inge Cornelis or call +32 473 65 15 77.
Course Details
Upcoming Session
29 May 2026, Live online
Early bird € 1 570
(until 24/04/2026)
(Full fee € 1 770)
Prices are excl. VAT
THE CONTENT
European HTA systems are undergoing significant change. While national differences in methodology and decision-making processes and criteria remain, increasing EU-level coordination is reshaping how companies must approach market and patient access strategies.
To succeed, pharma and biotech professionals involved in market and patient access planning need a solid grasp of the HTA landscape and how it is evolving. This course provides a practical introduction to current HTA dynamics in Europe, helping you make sense of both the fundamentals and the latest developments.
Over the course of one day, you will gain a better understanding of the variety in HTA processes and criteria across Europe and how these interact with EU-level developments.
If you are looking for a concise, expert-led overview of the latest HTA trends in Europe, with recommendations for access planning, this course is a must-attend.
Great overall introduction to the topic, with excellent details on the challenges to be dealt with in the new legislation. The interactive aspect and engaging presentation by Prof. Dr. Lieven Annemans, an obvious expert, were particularly valuable. The course deepened my understanding of HTA and provided a comprehensive overview of the topic.
Merck
Laura Bauer, Senior Manager, Global Policy & External Affairs - Germany - June 2024
THE EXPERT
Prof. Dr Lieven Annemans is one of Europe’s most respected voices in health economics and HTA.
He has experience in health economic evaluations across 20+ countries and numerous therapeutic areas.
He is a long-standing expert advisor in national and EU-level HTA initiatives, with deep insight into methodology, implementation, and policy.
He is an academic professor, past president of ISPOR, author of "Health Economics for Non-Economists", and has published more than 350 peer-reviewed papers. He's also a widely recognised speaker and trainer.
A CELforPharma faculty member since 2009, he is consistently praised for his engaging, pragmatic, and entertaining teaching style.
To get a flavour of Lieven’s expertise and teaching style, watch this recent educational webinar:
THE AUDIENCE & INTERACTIVE LEARNING FORMAT
This course is designed for pharma and biotech professionals who need a clear understanding of how HTA principles, policies, and practices affect market and patient access in Europe. It is especially valuable for executives working in:
Market Access
Pricing & Reimbursement
Clinical Development
Regulatory Affairs
Medical Affairs
Governmental Affairs
Health Economics
Marketing
The interactive format includes expert-led teaching, peer discussions, practical recommendations, and in-depth Q&A. You will learn directly from Prof. Dr Lieven Annemans and benefit from exchanging experiences with peers facing similar access challenges across Europe.
Great lecturer; the information covered during the training was very comprehensive, addressing both the basics and the latest developments. The overview of different models used in different EU countries was extremely valuable and the participant engagement in discussions was enriching. I highly recommend this course!
Insuvia
Monika Staniulyte, Regulatory Affairs Team Lead - Lithuania - June 2024
The different types of HTA processes in Europe and how they inform decision-making.
How HTA bodies combine a variety of evaluation criteria, and what this means for value assessment.
Key principles and common pitfalls in clinical evidence generation from an HTA perspective.
The role of Real-World Data in HTA, including its strengths, limitations, and appropriate use across the lifecycle.
What the Joint Clinical Assessment (JCA) will change, how to anticipate its implications, and how to prepare at a strategic level.
An excellent top-line overview of the practical application of health economics. The course covered a lot in a single day but remained digestible thanks to its clear format. I especially valued the discussion on current JCA developments. Peer input also added real value.
Kevin Veninga, Healthcare Communicator - The Netherlands - June 2025
| Definitions and Taxonomy of HTA: What HTA Is – and Is Not – and How It Functions in Decision-Making Contexts (~1 h) |
|
| Optimising the Mix of Criteria: Moving Beyond Cost-Effectiveness to Reflect Value, Need, and Societal Priorities (~1 h 30 min) |
|
| Generating Clinical Evidence: Designing Evidence That Stands Up to HTA Scrutiny (~45 min) |
|
| Lunch Break |
| The Increasing Need for Real-World Data (RWD): Managing Uncertainty and Evidence Gaps Across the Lifecycle (~1 h 15 min) |
|
| Towards a Joint Clinical Assessment (JCA) in the EU: What JCA Will Change — and What It Will Not (~1 h 30 min) |
|
| Summary & Final Discussion (~15 min) |
UPCOMING DATES & FORMATS - FEES
29 May 2026
Live online
Early bird € 1 570
(until 24/04/2026)
(Full fee € 1 770)
18 November 2026
Live online
Early bird € 1 570
(until 16/10/2026)
(Full fee € 1 770)
TIMING & LOCATION
Live Online: Zoom sessions between 9 AM and 5 PM CET (Brussels, Amsterdam, Paris time).
All practical details will be shared upon registration. For any questions, please contact Margherita Mutto or call +32 472 03 11 38 .
GROUP DISCOUNTS
Team discounts can be offered to 2 or more delegates from the same company.
Email Annelies Swaan for more details.
HOW TO REGISTER
Click the green “Register” button on your preferred course session.
The registration wizard will guide you through the process.Alternatively, download the offline registration form and send the completed form to Annelies Swaan.
PAYMENT OPTIONS
Credit Card: You’ll receive a secure payment link with your invoice (no immediate payment required).
Bank Transfer: Details provided with your invoice.
For help with registration, email Annelies Swaan or contact her by phone at +32 486 98 52 49.
INCLUDED IN THE REGISTRATION FEE
Access to a highly interactive, small-group online course (max 20 participants)
Course materials in both digital and hard copy format
Certificate of attendance signed by the experts and CELforPharma
VAT INFORMATION
Prices exclude VAT. VAT application depends on course format and your location:
Face-to-Face in Belgium: 21% Belgian VAT applies
Live online courses: The applicable VAT depends on your invoicing address. Contact your local VAT office for refund procedures where applicable.
TRANSFER & CANCELLATION POLICY
Flexible Transfer
If a registrant is unable to attend the scheduled course, they can avoid any cancellation charges by providing a suitable replacement participant.
Alternatively, the registrant may transfer once, on a 'space-available' basis and at no extra cost, to another course of the same value held within one year of the original course date, provided this is done at least three weeks prior to the event.
Registration Cancellation
Less than 14 days prior to the course date: The registrant is liable to pay the full invoiced registration fee.
Between 15 and 30 days prior to the course date: The registrant is liable to pay 50% of the invoiced registration fee.
More than 30 days prior to the course date: The registrant is liable to pay a cancellation fee of € 450 per registrant.
If a registrant postpones their participation to a future course and subsequently cancels again, no refund will be issued for the registration fees.
An excellent top-line overview of the practical application of health economics. The course covered a lot in a single day but remained digestible thanks to its clear format. I especially valued the discussion on current JCA developments. Peer input also added real value.
Kevin Veninga, Healthcare Communicator - The Netherlands - June 2025
Great overall introduction to the topic, with excellent details on the challenges to be dealt with in the new legislation. The interactive aspect and engaging presentation by Prof. Dr. Lieven Annemans, an obvious expert, were particularly valuable. The course deepened my understanding of HTA and provided a comprehensive overview of the topic.
Merck
Laura Bauer, Senior Manager, Global Policy & External Affairs - Germany - June 2024
The course and instructor were great. Lieven is clearly an expert in the field, with clear and articulate presentations. The interactions between attendees added to the experience, and I have gained valuable insights into the upcoming EU HTA changes. Highly recommended!
Novartis
Nick Riley, Senior Market Access Manager - Australia - June 2024
Great lecturer; the information covered during the training was very comprehensive, addressing both the basics and the latest developments. The overview of different models used in different EU countries was extremely valuable and the participant engagement in discussions was enriching. I highly recommend this course!
Insuvia
Monika Staniulyte, Regulatory Affairs Team Lead - Lithuania - June 2024
I got relevant information, it was refreshing also. The comparison of different countries' approaches and the excellent description of crucial parts of HTA were particularly useful. The experience from practice shared during the course enriched my understanding significantly.
Pharm-In
Dominik Grega, MA & HTA Manager - Slovakia - June 2024
People attending this course are typically also interested in the below courses.
Need help to find the right course? Email Inge Cornelis or call +32 473 65 15 77.